BiotechTube

Golimumab

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Ankylosing Spondylitis

Conditions

Ankylosing Spondylitis

Trial Timeline

Sep 3, 2012 → Apr 30, 2015

NCT ID
NCT01668004

About Golimumab

Golimumab is a approved stage product being developed by Merck for Ankylosing Spondylitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01668004. Target conditions include Ankylosing Spondylitis.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (6)

NCT IDPhaseStatus
NCT03270501Phase 3Completed
NCT03124121ApprovedCompleted
NCT02841176Pre-clinicalTerminated
NCT02318667ApprovedCompleted
NCT02092285ApprovedCompleted
NCT01668004ApprovedCompleted

Competing Products

20 competing products in Ankylosing Spondylitis

See all competitors
ProductCompanyStageHype Score
InfliximabCelltrionPhase 1
33
InfliximabCelltrionPhase 1
33
SUNPG1622 I dose + Placebo doseSun PharmaceuticalPhase 2
52
adalimumabEisaiPhase 3
77
Ixekizumab + Placebo + AdalimumabEli LillyPhase 3
77
Tramadol /acetaminophen + DiclofenacJohnson & JohnsonApproved
85
Golimumab + PlaceboJohnson & JohnsonPhase 3
77
GolimumabJohnson & JohnsonApproved
85
SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 2/3
65
placebo for risankizumab + risankizumabAbbViePhase 2
52
AdalimumabAbbVieApproved
85
Upadacitinib + PlaceboAbbViePhase 2
52
AdalimumabAbbViePre-clinical
23
infliximab + PlaceboMerckPhase 3
77
InfliximabMerckApproved
85
Infliximab + Placebo + NaproxenMerckPhase 3
77
InfliximabMerckPre-clinical
23
RemicadeMerckApproved
85
RemicadeMerckApproved
85
InfliximabMerckApproved
85

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85